Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite

Drug Metabolism and Disposition

Volumn 38, Issue 1, 2010, Pages 92-99

  Kazui, Miho ^a   Nishiya, Yumi ^a   Ishizuka, Tomoko ^a,c   Hagihara, Katsunobu ^a   Farid, Nagy A ^b   Okazaki, Osamu ^a   Ikeda, Toshihiko ^a,c   Kurihara, Atsushi ^a  

^a DAIICHI SANKYO CO   (Japan)

^b ELI LILLY AND COMPANY   (United States)

^c YOKOHAMA COLLEGE OF PHARMACY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXO CLOPIDOGREL; CLOPIDOGREL; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 4A11; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; ENZYME ANTIBODY; GLUTATHIONE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG ACTIVATION; DRUG METABOLISM; DRUG OXIDATION; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME KINETICS; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES; ARYL HYDROCARBON HYDROXYLASES; BIOCATALYSIS; BIOTRANSFORMATION; CELL LINE; CELL LINE, TUMOR; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; GLUTATHIONE; HUMANS; KETOCONAZOLE; KINETICS; MEPHENYTOIN; MICROSOMES; MICROSOMES, LIVER; NADP; OMEPRAZOLE; OXIDATION-REDUCTION; OXIDOREDUCTASES, N-DEMETHYLATING; PLATELET AGGREGATION INHIBITORS; SULFAPHENAZOLE; THEOPHYLLINE; TICLOPIDINE;

EID: 73149119363     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.029132     Document Type: Article

References (25)

1. Baker JAR, Oluyedun OA, Farid NA, Ring BJ, Wrighton SA, Kurihara A, and Guo Y (2008) Formation of the isomers of the active metabolite of prasugrel by allelic variants of the human cytochrome P450 isozymes [abstract]. Drug Metab Rev 40 (Suppl 3):244.
2. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, and Winters KJ (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5:2429-2436.
3. Clarke TA and Waskell LA (2003) The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 31:53-59.
4. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA, and Salazar DE (2007) Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 81:735-741.
5. Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG, Ernest CS, Salazar DE, Konkoy CS, and Winters KJ (2008) Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy 28: 1483-1494.
6. Gelboin HV, Krausz KW, Goldfarb I, Buters JT, Yang SK, Gonzalez FJ, Korzekwa KR, and Shou M (1995) Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. Biochem Pharmacol 50:1841-1850.
7. Hagihara K, Nishiya Y, Kurihara A, Kazui M, Farid NA, and Ikeda T (2008) Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel and ticlopidine. Drug Metab Pharmacokinet 23:412-420.
8. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, and Gaussem P (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-2247.
9. Kazui M, Ishizuka T, Yamamura N, Kurihara A, Naganuma H, Iwabuchi H, Takahashi M, Kawabata K, Yoneda K, Kita J, et al. (2001) Mechanism for production of pharmacologically active metabolites of CS-747, a new pro-drug ADP-receptor antagonist [abstract]. Thromb Haemostasis (Suppl):1916.
10. Krausz KW, Goldfarb I, Buters JT, Yang TJ, Gonzalez FJ, and Gelboin HV (2001) Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19. Drug Metab Dispos 29:1410-1423.
11. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, et al. (2009) Cytochrome P-450 polymorphism and response to clopidogrel. N Engl J Med 360:354-362.
12. Nishiya Y, Hagihara K, Kurihara A, Okudaira N, Farid NA, Okazaki O, and Ikeda T (2009) Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel and prasugrel. Xenobiotica 39:836-843.
13. Nishiya Y, Hagihara K, Ito T, Tajima M, Miura S, Kurihara A, Farid NA, and Ikeda T (2009) Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel. Drug Metab Dispos 37:589-593.
14. Ng PS, Imaoka S, Hiroi T, Osada M, Niwa T, Kamataki T, and Funae Y (2003) Production of inhibitory polyclonal antibodies against cytochrome P450s. Drug Metab Pharmacokinet 18:163-172.
15. Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert JM, Maffrand JP, and Picard C (2002) Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 30:1288-1295.
16. Richter T, Mürdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, and Zanger UM (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308:189-197.
17. Rowland Yeo K, Rostami-Hodjegan A, and Tucker GT (2004) Abundance of cytochromes P450 in human liver: a meta-analysis. Br J Clin Pharmacol 57:687-688.
18. Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, and Ring BJ (2006) Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 34:600-607.
19. Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, Defreyn G, and Maffrand JP (1992) Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 44:527-532.
20. Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y, and Herbert JM (1994) The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 72:313-317.
21. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, and Herbert JM (2000) Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891-896.
22. Savi P and Herbert JM (2005) Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 31:174-183.
23. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L, et al. (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363-375.
24. Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ, Lee DS, Sohn DW, Lee MM, and Kim HS (2006) Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 174:1715-1722.
25. Takahashi M, Pang H, Kawabata K, Farid NA, and Kurihara A (2008) Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. J Pharm Biomed Anal 48:1219-1224.